Date: 2018-04-25
Type of information: Nomination
Compound: member of the board of directors
Company: Syntimmune (USA - MA)
Therapeutic area: Autoimmune diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 25, 2018, Syntimmune announced an expansion of its board of directors with the appointment of Andrew Cheng, the chief medical officer and an executive vice president at Gilead Sciences .Dr. Cheng has a 20-year track record of accomplishments, including leading the formulation of Phase 1-4 clinical development plans as well as the filing and approval of NDA and MAA submissions for 11 approved HIV products. His past roles at Gilead include leading the company’s development operations, which covered clinical research support in multiple therapeutic areas including oncology, inflammatory, respiratory and cardiovascular indications as well as HIV and liver diseases. Dr. Cheng holds an M.D. and a Ph.D. in cellular and molecular biology from Columbia University.
Financial terms:
Latest news:
Is general: Yes